Pfizer’s Migraine Drug Approval Triggers $475M Payment to Royalty Pharma
FDA approval of Pfizer nasal spray migraine drug Zavzpret last week means a $475 million payday for Royalty Pharma. The payment stems from a financing deal Pfizer inherited when it acquired rights to the…
Continue Reading